- Home
- PRAX
as 11-15-2024 4:00pm EST
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 1.2B | IPO Year: | 2020 |
| Target Price: | $146.33 | AVG Volume (30 days): | 317.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -9.95 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.25 - $86.93 | Next Earning Date: | 11-06-2024 |
| Revenue: | $1,605,000 | Revenue Growth: | -16.93% |
| Revenue Growth (this year): | -40.34% | Revenue Growth (next year): | -32.72% |
Latest Praxis Precision Medicines Inc. News
PRAX Breaking Stock News: Dive into PRAX Ticker-Specific Updates for Smart Investing
Simply Wall St.
9 days ago
Praxis Precision Medicines Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
GuruFocus.com
10 days ago
Praxis Precision Medicines Inc (PRAX) Q3 2024 Earnings Call Highlights: Strong Cash Position ...
GlobeNewswire
10 days ago
Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences
MT Newswires
11 days ago
Wedbush Raises Praxis Precision Medicines Price Target to $57 From $51, Maintains Neutral Rating
MT Newswires
11 days ago
Praxis Precision Medicines Q3 Net Loss Widens, Collaboration Revenue Falls; Shares Drop Pre-Bell
Zacks
11 days ago
Praxis Precision Medicines, Inc. (PRAX) Reports Q3 Loss, Misses Revenue Estimates
GlobeNewswire
11 days ago
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results
GlobeNewswire
16 days ago
Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024
Compare PRAX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PRAX Praxis Precision Medicines Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.